clinical trial · NCT03022097
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
AstraZeneca·phase3·completed·n = 1,625
COPDAclidinium bromide/formoterol Fixed-Dose CombinationAclidinium bromideFormoterol FumaratePlacebo
brief summary
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).
started
Feb 2, 2017
primary completion
Apr 14, 2022
completion
Apr 14, 2022
last updated
Mar 26, 2025
official title
A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol